SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read More
Tag: Vosevi
NICE nod for Gilead’s pan-genotypic hepatitis C therapy
Gilead’s pan-genotypic treatment for hepatitis C Vosevi has won the National Institute for Health and Care Excellence’s seal of approval for use on the NHS.
Read More
New hepatitis C therapies approved in Europe
Patients with hepatitis C in Europe could soon gain access to two new pan-genotypic treatment options after the European Commission issued approval for AbbVie’s Maviret and Gilead’s Vosevi following an accelerated review.
Read More
US nod for Gilead’s pan-genotypic hep C pill
The US Food and Drug Administration has waved through Gilead’s new hepatitis C therapy Vosevi, offering adults with all genotypes of the condition a new treatment option in the form of three medicines in a single pill.
Read More
EMA advisors back eight medicines for approval
Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
